Biomarkers Market Summary

The global biomarkers market size was estimated at USD 81.04 billion in 2023 and is projected to reach USD 194.21 billion by 2030, growing at a CAGR of 13.36% from 2024 to 2030. The growth of this market is primarily driven by the rising prevalence of cancer and other chronic diseases, the increasing significance of companion diagnostics, growing investments in biomedical research, and continuous innovations emerging from ongoing scientific studies. Biomarkers are playing an increasingly critical role in disease diagnosis, prognosis, personalized medicine, and drug development, making them essential tools for modern healthcare.

For instance, in February 2023, the National Institutes of Health announced funding of USD 4 million to Eastern Virginia Medical School (EVMS) to support research and development of biomarkers for the early detection of aggressive prostate cancer. The prevalence of fatal and chronic diseases, including cancer, diabetes, cardiovascular disorders, and other lifestyle-related illnesses, has been rising steadily in recent years. Lifestyle changes, such as sedentary behavior, poor dietary habits, and environmental factors, have contributed significantly to this trend, highlighting the urgent need for advanced diagnostic tools and targeted therapies, thereby fueling the demand for biomarkers.

Key Market Trends & Insights

• North America led the biomarkers market with a revenue share of 43.94% in 2023, supported by well-established healthcare infrastructure, high research investment, and early adoption of advanced diagnostic technologies.
• Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030, driven by increasing healthcare expenditure, rising disease prevalence, and growing awareness about personalized medicine in countries such as China, India, and Japan.
• Based on type, the safety biomarkers segment held the largest revenue share of 37.62% in 2023, reflecting their critical role in evaluating adverse effects, drug safety, and patient monitoring.
• Based on product, the consumables segment led the market in 2023, encompassing reagents, kits, and other essential materials required for biomarker analysis and research.
• Based on application, the drug discovery and development segment dominated the market in 2023, highlighting the importance of biomarkers in identifying novel drug targets, optimizing clinical trials, and accelerating the development of effective therapies.
• Based on disease, the cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030, due to the high global incidence of cancer and the critical role of biomarkers in early detection, prognosis, and treatment monitoring.

Order a free sample PDF of the Biomarkers Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 81.04 Billion
• 2030 Projected Market Size: USD 194.21 Billion
• CAGR (2024-2030): 13.36%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some of the leading market players include F. Hoffmann-La Roche AG, Abbott, QIAGEN, and PerkinElmer Incorporated. Key players are focusing on geographic expansions and gaining market approvals for innovative products. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process & analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.

Atlas Genetics Ltd.; Hologic, Inc.;Myriad Genetics, Inc.; and Genomic Health, Inc. are some of the emerging market participants. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues.

Key Players

• Hoffmann-La Roche AG
• Epigenomics AG
• Abbott
• Thermo Fisher Scientific Inc
• General Electric
• Eurofins Scientific
• Johnson & Johnson Services, Inc.
• QIAGEN
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Merck KGaA
• PerkinElmer Inc.
• Agilent Technologies, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global biomarkers market is projected to witness robust growth, driven by rising prevalence of chronic diseases, increasing importance of companion diagnostics, and continuous research innovations. North America remains the largest market due to advanced healthcare infrastructure and research funding, while Asia Pacific is expected to grow fastest owing to rising healthcare investment and disease awareness. Safety biomarkers, consumables, and applications in drug discovery dominate the market, with cancer remaining the leading focus area. Increasing adoption of biomarkers in personalized medicine, early disease detection, and targeted therapy development underscores their essential role, ensuring sustained market expansion through 2030.